阿奇霉素改善检查指征宫颈环扎术潜伏期的多中心随机对照试验
这项在美国4个中心开展的开放标签随机对照试验纳入54例单胎妊娠、孕24周前无痛性宫颈扩张行检查指征宫颈环扎术者,比较围术期标准治疗(头孢唑林+吲哚美辛)加用或不加用阿奇霉素的妊娠潜伏期。意向性分析显示两组从环扎到分娩的中位潜伏期无差异(92天 vs 85天,P=.93),次要产科和新生儿结局亦无统计学显著差异。
要点
- 检查指征宫颈环扎术围术期在头孢唑林和吲哚美辛基础上加用单剂阿奇霉素,未改善分娩潜伏期。
- 意向性分析中,阿奇霉素组与对照组中位潜伏期分别为92天和85天(P=.93)。
- 次要产科及新生儿结局在两组间均无统计学显著差异。
核心结论
- 在单胎妊娠行检查指征宫颈环扎术的患者中,围术期单剂阿奇霉素加用于标准治疗头孢唑林和吲哚美辛,与单纯标准治疗相比未改善分娩潜伏期或其他围产期结局。
研究设计与样本
- 开放标签多中心随机对照试验,2021年12月至2023年9月在美国4个中心开展,纳入单胎妊娠行检查指征宫颈环扎术者。
- 共评估82例,随机54例,对照组27例、阿奇霉素组27例,按中心分层1:1计算机随机。
- 对照组为标准治疗:头孢唑林1-2 g静脉注射及术前吲哚美辛50 mg,术后8和16小时各追加2剂;阿奇霉素组在此基础上加用阿奇霉素1000 mg静脉注射。
- 主要结局为从环扎到分娩的妊娠潜伏期(天),次要结局包括早产、分娩孕周、绒毛膜羊膜炎及新生儿发病率和死亡率。
主要发现
- 意向性分析中,阿奇霉素组与对照组从环扎到分娩的中位潜伏期无差异(92天[四分位距45-118] vs 85天[四分位距20-123],P=.93)。
- 次要产科和新生儿结局均未发现统计学显著差异。
临床怎么用
- 原文结论为单剂围术期阿奇霉素加用于标准治疗未改善分娩潜伏期或其他围产期结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Physical examination-indicated cerclage is an intervention offered to prolong pregnancy in the setting of painless cervical dilation before 24 weeks of gestation. Of note, 1 randomized clinical trial showed an increased incidence of pregnancy prolongation by at least 28 days among participants who received perioperative indomethacin and cefazolin in the setting of a physical examination-indicated cerclage compared with those who did not receive those perioperative medications. Prospective studies have suggested that prophylactic azithromycin may increase latency in the setting of cervical shortening. However, this has not been studied in a controlled manner in patients undergoing physical examination-indicated cerclage. OBJECTIVE: This study aimed to determine whether the addition of perioperative azithromycin to cefazolin and indomethacin for physical examination-indicated cerclage increases the latency to delivery compared with perioperative cefazolin and indomethacin alone. STUDY DESIGN: This was an open-label multicenter randomized controlled trial of individuals with singleton gestations who were undergoing a physical examination-indicated cerclage between December 2021 and September 2023 at 4 sites across the United States. This study was approved by the institutional review board and was registered on ClinicalTrials.gov (registration number: NCT05132829). Participants were randomized 1:1 via a computer-generated randomization sequence stratified by site to standard of care (cefazolin 1-2 g intravenously and indomethacin 50 mg preoperatively followed by 2 additional doses at 8 and 16 hours postoperatively, control arm) or standard of care plus azithromycin (azithromycin 1000 mg intravenously in addition to cefazolin and indomethacin described in the control group, azithromycin arm). The primary outcome was gestational latency (days) from cerclage placement to delivery. The secondary outcomes included preterm birth, gestational age at delivery, chorioamnionitis, and neonatal morbidity and mortality. RESULTS: A total of 82 pregnant individuals were assessed for eligibility, and 54 participants were randomized, 27 to the control arm and 27 to the azithromycin arm. In the primary intention-to-treat analysis, the median gestational latency from cerclage placement to delivery did not differ between the intervention and control groups (92 days [interquartile range, 45-118] vs 85 [interquartile range, 20-123] days, respectively; P=.93). Furthermore, there was no statistically significant difference found in any of the secondary obstetrical or neonatal outcomes. CONCLUSION: A single perioperative dose of azithromycin in addition to standard of care cefazolin and indomethacin does not improve the latency to delivery or other perinatal outcomes compared with standard of care alone in patients with singleton gestations undergoing a physical examination-indicated cerclage.
引用
- Jayakumaran JS, Khanuja K, Fischer SA, et al. Azithromycin to improve latency in examination-indicated cerclage: a multicenter randomized controlled trial. Am J Obstet Gynecol MFM. 2025. PMID: 41135925. doi:10.1016/j.ajogmf.2025.101818
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。